Clinical Trials Logo

Clinical Trial Summary

This is a non-interventional retrospective multi-center study for the patients received Entekavir or TDF for Hepatitis B prophylaxis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06049602
Study type Observational
Source Viral Hepatitis Society
Contact Fehmi Tabak, Prof
Phone +905322763788
Email fehmitabak@yahoo.com
Status Recruiting
Phase
Start date January 15, 2023
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Recruiting NCT04442841 - HBV Vaccine in Anti-core Positive Donors After LT Phase 2
Active, not recruiting NCT01907230 - Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients Phase 4
Recruiting NCT04619082 - TAF to Prevent HBV Reactivation in Cancer Patients Phase 4
Completed NCT02555943 - DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) Phase 2/Phase 3
Recruiting NCT01914744 - Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL Phase 2
Enrolling by invitation NCT04942886 - Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation N/A